Leveraging human genetics to guide drug target discovery
نویسندگان
چکیده
منابع مشابه
Leveraging Big Data to Transform Target Selection and Drug Discovery
The advances of genomics, sequencing, and high throughput technologies have led to the creation of large volumes of diverse datasets for drug discovery. Analyzing these datasets to better understand disease and discover new drugs is becoming more common. Recent open data initiatives in basic and clinical research have dramatically increased the types of data available to the public. The past fe...
متن کاملTarget validation: A door to drug discovery.
From ancient times to today, drug discovery transitioned from serendipity to rationality over its long history. Proper drug target selection and validation are crucial to the discovery of new drugs. This review discusses the definition of drug targets and proposes several characteristics for drug targets. The limitations of the term 'target' itself are summarized. The drug target validation pro...
متن کاملHuman-Yeast Hybrids: New Visions to Genetic Disorders and Drug Discovery
Yeast has been a very helpful organism for centuries, especially with respect to fermentation of sugars and production of bread. However, for an even longer time, yeast has been a distant relative of humans having diverged from a common ancestor, about one billion years ago. More than one third of the yeast genes have human counterparts, despite this evolutionary distance. Yeast and human ortho...
متن کاملDrug target ontology to classify and integrate drug discovery data
BACKGROUND One of the most successful approaches to develop new small molecule therapeutics has been to start from a validated druggable protein target. However, only a small subset of potentially druggable targets has attracted significant research and development resources. The Illuminating the Druggable Genome (IDG) project develops resources to catalyze the development of likely targetable,...
متن کاملDrug–Target Kinetics in Drug Discovery
The development of therapies for the treatment of neurological cancer faces a number of major challenges including the synthesis of small molecule agents that can penetrate the blood-brain barrier (BBB). Given the likelihood that in many cases drug exposure will be lower in the CNS than in systemic circulation, it follows that strategies should be employed that can sustain target engagement at ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Trends in Cardiovascular Medicine
سال: 2017
ISSN: 1050-1738
DOI: 10.1016/j.tcm.2016.08.008